公开(公告)号：US08048992B2

公开(公告)日：2011-11-01

申请号：US11885245

申请日：2006-02-22

申请人： Yoshikazu Kurosawa ,  Yasushi Akahori ,  Nobuhiro Takahashi ,  Atsushi Sugioka ,  Nobuhiro Hayashi ,  Akihiko Takasaki ,  Kazuhiro Suzuki ,  Miwa Morita ,  Gene Kurosawa ,  Sari Fujiyama ,  Susumu Tsustumi ,  Keiko Ogawa ,  Kazuki Matsuda ,  Chiho Muramatsu ,  Yoshitaka Iba ,  Mariko Sumitomo ,  Masachika Azuma ,  Yoshinori Ukai ,  Kazuhiro Morishita

发明人： Yoshikazu Kurosawa ,  Yasushi Akahori ,  Nobuhiro Takahashi ,  Atsushi Sugioka ,  Nobuhiro Hayashi ,  Akihiko Takasaki ,  Kazuhiro Suzuki ,  Miwa Morita ,  Gene Kurosawa ,  Sari Fujiyama ,  Susumu Tsustumi ,  Keiko Ogawa ,  Kazuki Matsuda ,  Chiho Muramatsu ,  Yoshitaka Iba ,  Mariko Sumitomo ,  Masachika Azuma ,  Yoshinori Ukai ,  Kazuhiro Morishita

IPC分类号： C07K16/00

CPC分类号： C07K16/303 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2319/00 ,  G01N33/57426 ,  G01N33/57438

摘要： It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.

摘要翻译： 旨在澄清可用作治疗或诊断癌症并在医学领域或研究领域中利用分子的靶标的分子。 通过用抗体处理被鉴定为特异性表达于肺癌细胞中的分子的IgSF4，并施加ADCC活性。 基于该发现，提供了抗IgSF4抗体作为治疗癌症等的手段。

公开(公告)号：US20090053243A1

公开(公告)日：2009-02-26

申请号：US11885245

申请日：2006-02-22

申请人： Yoshikazu Kurosawa ,  Yasushi Akahori ,  Nobuhiro Takahashi ,  Atsushi Sugioka ,  Nobuhiro Hayashi ,  Akihiko Takasaki ,  Kazuhiro Suzuki ,  Miwa Morita ,  Gene Kurosawa ,  Sari Fujiyama ,  Susumu Tsustumi ,  Keiko Ogawa ,  Kazuki Matsuda ,  Chiho Muramatsu ,  Yoshitaka Iba ,  Mariko Sumitomo ,  Masachika Azuma ,  Yoshinori Ukai ,  Kazuhiro Morishita

发明人： Yoshikazu Kurosawa ,  Yasushi Akahori ,  Nobuhiro Takahashi ,  Atsushi Sugioka ,  Nobuhiro Hayashi ,  Akihiko Takasaki ,  Kazuhiro Suzuki ,  Miwa Morita ,  Gene Kurosawa ,  Sari Fujiyama ,  Susumu Tsustumi ,  Keiko Ogawa ,  Kazuki Matsuda ,  Chiho Muramatsu ,  Yoshitaka Iba ,  Mariko Sumitomo ,  Masachika Azuma ,  Yoshinori Ukai ,  Kazuhiro Morishita

IPC分类号： A61K39/395 ,  C07K16/18 ,  C12N15/11 ,  C12N15/00 ,  A61P31/00 ,  C12N5/06 ,  G01N33/574

CPC分类号： C07K16/303 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2319/00 ,  G01N33/57426 ,  G01N33/57438

摘要： It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.

摘要翻译： 旨在澄清可用作治疗或诊断癌症并在医学领域或研究领域中利用分子的靶标的分子。 通过用抗体处理被鉴定为特异性表达于肺癌细胞中的分子的IgSF4，并施加ADCC活性。 基于该发现，提供了抗IgSF4抗体作为治疗癌症等的手段。

公开(公告)号：US20120046451A1

公开(公告)日：2012-02-23

申请号：US13238096

申请日：2011-09-21

申请人： Yoshikazu Kurosawa ,  Yasushi Akahori ,  Nobuhiro Takahashi ,  Atsushi Sugioka ,  Nobuhiro Hayashi ,  Akihiko Takasaki ,  Kazuhiro Suzuki ,  Miwa Morita ,  Gene Kurosawa ,  Sari Fujiyama ,  Susumu Tsutsumi ,  Keiko Ogawa ,  Kazuki Matsuda ,  Chiho Muramatsu ,  Yoshitaka Iba ,  Mariko Sumitomo ,  Masachika Azuma ,  Yoshinori Ukai ,  Kazuhiro Morishita

发明人： Yoshikazu Kurosawa ,  Yasushi Akahori ,  Nobuhiro Takahashi ,  Atsushi Sugioka ,  Nobuhiro Hayashi ,  Akihiko Takasaki ,  Kazuhiro Suzuki ,  Miwa Morita ,  Gene Kurosawa ,  Sari Fujiyama ,  Susumu Tsutsumi ,  Keiko Ogawa ,  Kazuki Matsuda ,  Chiho Muramatsu ,  Yoshitaka Iba ,  Mariko Sumitomo ,  Masachika Azuma ,  Yoshinori Ukai ,  Kazuhiro Morishita

IPC分类号： C07K16/42

CPC分类号： C07K16/303 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2319/00 ,  G01N33/57426 ,  G01N33/57438

摘要： It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.

摘要翻译： 旨在澄清可用作治疗或诊断癌症并在医学领域或研究领域中利用分子的靶标的分子。 通过用抗体处理被鉴定为特异性表达于肺癌细胞中的分子的IgSF4，并施加ADCC活性。 基于该发现，提供了抗IgSF4抗体作为治疗癌症等的手段。

公开(公告)号：US20090203538A1

公开(公告)日：2009-08-13

申请号：US12318829

申请日：2009-01-09

申请人： Atsushi Sugioka ,  Mototaka Sugiura ,  Yasushi Akahori ,  Nobuhiro Hayashi ,  Akihiko Takasaki ,  Miwa Morita ,  Gene Kurosawa ,  Mariko Sumitomo ,  Susumu Tsutsumi ,  Keiko Ogawa ,  Kazuki Matsuda ,  Chiho Muramatsu ,  Noriko Satou ,  Masachika Azuma ,  Yoshinori Ukai ,  Kazuhiro Suzuki ,  Yoshikazu Kurosawa ,  Miho Tanaka ,  Mamoru Shiraishi

发明人： Atsushi Sugioka ,  Mototaka Sugiura ,  Yasushi Akahori ,  Nobuhiro Hayashi ,  Akihiko Takasaki ,  Miwa Morita ,  Gene Kurosawa ,  Mariko Sumitomo ,  Susumu Tsutsumi ,  Keiko Ogawa ,  Kazuki Matsuda ,  Chiho Muramatsu ,  Noriko Satou ,  Masachika Azuma ,  Yoshinori Ukai ,  Kazuhiro Suzuki ,  Yoshikazu Kurosawa ,  Miho Tanaka ,  Mamoru Shiraishi

IPC分类号： C40B30/04 ,  G01N33/567 ,  G01N33/574 ,  C07K16/00 ,  C40B40/10 ,  C40B60/10

CPC分类号： C07K16/30 ,  C07K16/005 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/303 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C12N15/1138 ,  C12N2310/14 ,  G01N33/57492 ,  G01N33/6854

摘要： It is intended to provide a method whereby a plural number of antibodies against cell surface antigens are quickly classified and to provide a method whereby antigens of the thus classified antibodies are quickly identified. Further, it is intended to provide a method of promoting the utilization of the useful data obtained by the above methods. Furthermore, it is intended to provide an antibody which is effective in treating or diagnosing cancer. Namely, a method of classifying antibodies which comprises: (1) the step of preparing a plural number of antibodies respectively recognizing cell surface antigens; (2) the step of bringing each of these antibodies into contact with a cell of the same species; (3) the step of analyzing each of the cells having been treated in the step (2) by flow cytometry and thus obtaining data indicating the reactivity of each antibody with its cell surface antigen; and (4) the step of comparing the thus obtained data and classifying the individual antibodies depending on the similarity. A method of identifying antigens which further comprises: (5) the step of selecting one to several antibodies from each antibody group formed in the step (4) and identifying antigens thereof; and (6) on the assumption that antigens of the antibodies belonging to a single antibody group are the same or highly related to one another, making relations between the antigens having been identified in the step (5) and the antibody groups to thereby identify the antigens. An antibody against HER1, an antibody against HER2, an antibody against CD46, an antibody against ITGA3, an antibody against ICAM1, an antibody against ALCAM, an antibody against CD147, an antibody against C1qR, an antibody against CD44, an antibody against CD73, an antibody against EpCAM and an antibody against HGFR, each obtained by using the above methods.